Background This study is a multi-centre, open-label, randomised controlled trial that will compare the impact of selective internal radiation therapy (SIRT) using SIR-Spheres® yttrium-90 microspheres versus sorafenib on overall survival in patients with locally advanced hepatocellular carcinoma (HCC). A definitive RCT comparing the 2 most promising therapies in locally-advanced HCC will impact on outcomes in a large number of patients and change clinical practice. This will also pave the way for future trials in combined modality therapies in HCC. Methods The study is structured so that patients with locally advanced HCC, who satisfy the study eligibility criteria, will be randomised to receive either: Treatment Arm A: Oral Sorafenib therapy at a dose of 400 mg b.i.d until disease progression, no further response, complete regression or unacceptable toxicity or Treatment Arm B: A single administration of SIR-Spheres into the liver targeted at HCC in the liver by the trans-arterial route. Results Twenty patients treated with 90Y-RE and nineteen patients received Sorafenib at our institution from 14 March 2011, and 30 June 2016 were included. Data from 39 consecutive patients were analyzed. The majority of patients were Child Pugh class B(90%), Barcelona Clinic liver Cancer(BCLC) stage C(58.5%) and Okuda class I (89.5%). Approximately 71% patients diagnosed in IIIa stage and 70% of patients had HBV infection. In the analysis for best response, three of 20 patients in the SIRT group (15%) achieved a partial response 7 of 19 patients (46%) had stable disease, whereas in Sorafenib group, two of 19 patients in the SIRT group (12%) achieved a partial response 9 of 19 patients (39%) had stable disease. Conclusion This study shows the potential efficacy of SIR-Spheres and sorafenib. In summary, selective internal radiation therapy (SIRT) using SIR-Spheres is a promising treatment for well selected patients with unresectable HCC. Sorafenib is effective for the patients with locally advanced HCC without portal vein thrombosis (PVT).

The goal of this study is making the value of Mongolian people about Mongolian traditional medicine (TM) and non-traditional medicine (NTM). Totally, 694 citizens involved from Ulaanbaatar city, Nalaikh District and 7 provinces (Selenge, Darkhan, Sukhbaatar, GoviAltai, Tov, Zavhan, Dundgovi, and Hovsgol) of Mongolia. The citizens included with age between 20-70. We used of questionnaire randomly, from February to May of 2015. The 69.1% of 694 citizens was between the 20-40 age, and 63% were female and 37% were male. In this study, the 43% of all subjects was described to use both all medicines and 25% was traditional medicine, 32% was non-traditional medicine. However, in the cancer 14,8% was nontraditional medicine, 20.6% traditional medicine, 31.8% was used a combination of traditional medicine and non traditional medicine. The 58% of all subjects describe to an know that evaluate to diagnose by pulse palpation, to evaluating the image, using traditional drugs and other methods. The 60% of all subjects describe that treatment advantage Traditional medicine and 40% non-traditional medicine. Whether the adverse effects of treatment, 38% wasn’t of traditional medicine and 32% wasn’t non-traditional medicine. To getting the information about traditional medicine, 86% was from own families, friends and journal, and 14% from other sources. Most of the citizens (43 %) used a combination of TM and NTM. The satisfaction was 60% for TM, this seems to be caused of closer to the patient .